InVivo Therapeutics scaffold device may improve spinal cord injury — 4 key insights

Spinal Tech

An investigational scaffold device from InVivo Therapeutics increases the likelihood that a patient with acute thoracic complete spinal cord injury will have a neurologic status 'conversion' from complete paraplegia to incomplete injury, according to findings presented at the American Association of Neurological Surgeons 2018 Annual Meeting in New Orleans and detailed in Medscape.

Here are four things to know.

1. The prospective INSPIRE (INvivo study of Probable Benefit of the Neuro-SPInal Scaffold for Safety and Neurologic REcovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) study which evaluated the device in 19 patients from 11 study sites.

2. All patients had complete SCI with T1 or T2 neurologic levels of injury, visible contusions on MRI but no cord transections or traumatic brain injuries and underwent open stabilization surgery less than 96 hours after the injury onset.

3. The trial's primary endpoint was American Spinal Injury Association Impairment Scale conversion at 6 months. This was achieved in 44 percent of patients, greater than the 25 percent objective performance criterion of the study design.

4. The investigational scaffold device, a small porous biodegradable structure made of polyglycolic acid and polylysine, was implanted into the spinal cord at the injury site.

More articles on devices and implants:

Medtronic expands paid family leave benefits: 5 things to know

InVivo Therapeutics reports a $4.8M net loss in 2018 Q1: 5 details

SeaSpine reports $33.2M in 2018 Q1 revenue: 6 things to know

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers